Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes.
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Diabetes and weight-loss medications, known as GLP-1 or incretin drugs, have taken the world by storm — especially the United ...